Breaking News Instant updates and real-time market news.

ETTX

Entasis Therapeutics

$6.14

(0.00%)

13:12
11/14/18
11/14
13:12
11/14/18
13:12

Entasis Therapeutics reports Q3 net loss ($8.5M) vs. ($8.3M) last year

Entasis earlier today reported a net loss of $8.5M for the third quarter 2018 as compared to $8.3M for the prior year period. The increase in net loss for the quarter was primarily related to increases in research and development expenses, as well as increases in general and administrative expenses primarily related to professional fees associated with the company's preparation for its IPO. These increases are offset by an increase in grant income.Research and development expenses were $8.1M for the third quarter 2018 as compared to $7.2M for the prior year period. The increase in research and development expenses was primarily driven by an increase in spending for preclinical and clinical development activities associated with the advancement of the company's pipeline. Entasis ended the quarter with $94M in cash and cash equivalents compared to $55.1M as of December 31, 2017. continues to advance its pre-clinical program on a novel class of non beta-lactam penicillin-binding protein inhibitors or NBPs, with an initial focus on multi-drug resistant Pseudomonas infections. Lead optimization work is ongoing with the goal of selecting a clinical candidate in 2019. The company is on track to initiate two Phase 3 clinical trials in 2019.

ETTX Entasis Therapeutics
$6.14

(0.00%)

11/08/18
FBCO
11/08/18
NO CHANGE
Target $18
FBCO
Outperform
NEJM article on Entasis' Zoli increases awareness, validates novelty, says Credit Suisse
Credit Suisse analyst Martin Auster notes that Entasis Therapeutics' Phase 2 trial produced positive results, per protocol, demonstrating Zoliflodacin's potential impact on the growing antibiotic-resistance epidemic. As characterized by an NEJM editorial, N. gonorrhea can be a devastating infection if untreated, so the emergence of antibiotic-resistant strands is rather troublesome, he contends, adding that the article describes Zoli's single-dose regimen as "promising," owing to the challenges that occur when following up with patients. Auster continues to believe that an oral, single dose alternative to the SoC will add visibility and credibility to the company's novel pipeline. The analyst reiterates an Outperform rating and $18 price target on the shares.
10/24/18
10/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at JMP Securities. 2. Comcast (CMCSA) resumed with a Buy at Deutsche Bank, reinstated with a Buy at Citi, and assumed with a Neutral at Guggenheim. 3. 2U (TWOU) initiated with a Buy at Needham. 4. Corbus Pharmaceuticals (CRBP) initiated with a Buy at B. Riley FBR. 5. Entasis Therapeutics (ETTX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/18
RHCO
10/24/18
INITIATION
Target $20
RHCO
Buy
Entasis Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Entasis Therapeutics with a Buy rating and a price target of $20, saying the company is "uniquely positioned by targeting bacterial infections where few therapeutic options exist" while also "increasing rates of multi-drug resistance". The analyst notes that Entasis' lead antibiotic "has the potential to grab significant market share as the drug will target well-defined patient populations with limited treatment options" given up to 200K of registered Acinetobacter infections in the U.S. and the E.U.
10/22/18
FBCO
10/22/18
INITIATION
Target $18
FBCO
Outperform
Entasis Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started Entasis Therapeutics with an Outperform rating and $18 price target. The analyst notes that Entasis has two Phase 3-ready assets, with ETX2514 being the key value driver for the stock. ETX2514 is being developed to address difficult-to-treat Acinetobacter infections, and has shown promising preclinical efficacy, good tissue distribution, and a clean safety profile to date, he contends. Auster is modeling a 45% probability of success to this program, but projects a potential $400M global peak opportunity by 2033 in this setting.

TODAY'S FREE FLY STORIES

HAS

Hasbro

$84.57

-0.26 (-0.31%)

12:30
12/13/18
12/13
12:30
12/13/18
12:30
Options
July 95 strike call buyer in Hasbro tied to hedge »

July 95 strike call buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
12/13/18
12/13
12:25
12/13/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

CSTM

Constellium

$8.19

-0.22 (-2.62%)

12:25
12/13/18
12/13
12:25
12/13/18
12:25
Conference/Events
Constellium to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 17

    Dec

  • 18

    Dec

SBUX

Starbucks

$66.32

0.22 (0.33%)

12:25
12/13/18
12/13
12:25
12/13/18
12:25
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

BABA

Alibaba

$151.67

0.18 (0.12%)

, YOKU

Youku Tudou

$0.00

(0.00%)

12:23
12/13/18
12/13
12:23
12/13/18
12:23
Hot Stocks
Alibaba's Youku to host highlights, documentary content from NFL »

Youku (YOKU), the Alibaba…

BABA

Alibaba

$151.67

0.18 (0.12%)

YOKU

Youku Tudou

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

FIZZ

National Beverage

$79.84

-4.28 (-5.09%)

, STZ

Constellation Brands

$182.12

-4.58 (-2.45%)

12:21
12/13/18
12/13
12:21
12/13/18
12:21
Conference/Events
UBS beverages analyst to hold an analyst/industry conference call »

Beverages Analyst Sean…

FIZZ

National Beverage

$79.84

-4.28 (-5.09%)

STZ

Constellation Brands

$182.12

-4.58 (-2.45%)

PEP

PepsiCo

$118.01

1.03 (0.88%)

CCE

Coca-Cola European Partners

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BF.B

Brown-Forman, also tag with BFA, BFB

$46.92

0.44 (0.95%)

MNST

Monster Beverage

$53.60

-3.84 (-6.69%)

SAM

Boston Beer

$263.73

-10.35 (-3.78%)

KDP

Keurig Dr Pepper

$26.14

0.03 (0.11%)

TAP

Molson Coors

$63.13

0.12 (0.19%)

KO

Coca-Cola

$49.45

0.25 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Dec

  • 18

    Dec

  • 15

    Feb

  • 03

    Mar

VRTX

Vertex

$171.99

-3.56 (-2.03%)

12:20
12/13/18
12/13
12:20
12/13/18
12:20
Options
Sudden burst of activity in Vertex Pharma weekly calls »

Sudden burst of activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.31

0.59 (8.78%)

, AAPL

Apple

$170.93

1.84 (1.09%)

12:20
12/13/18
12/13
12:20
12/13/18
12:20
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been…

GE

General Electric

$7.31

0.59 (8.78%)

AAPL

Apple

$170.93

1.84 (1.09%)

TSLA

Tesla

$371.13

4.37 (1.19%)

QD

Qudian

$6.47

1.21 (23.00%)

CIEN

Ciena

$34.64

2.505 (7.80%)

LLNW

Limelight Networks

$2.39

-0.81 (-25.31%)

TLRD

Tailored Brands

$14.13

-6.03 (-29.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

ISRG

Intuitive Surgical

$511.49

-4.22 (-0.82%)

12:19
12/13/18
12/13
12:19
12/13/18
12:19
Recommendations
Intuitive Surgical analyst commentary  »

Piper still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GH

Guardant Health

$41.25

-1.16 (-2.74%)

, AZN

AstraZeneca

$39.11

0.2 (0.51%)

12:17
12/13/18
12/13
12:17
12/13/18
12:17
Hot Stocks
Guardant Health, AstraZeneca partner to develop companion diagnostics tests »

Guardant Health (GH)…

GH

Guardant Health

$41.25

-1.16 (-2.74%)

AZN

AstraZeneca

$39.11

0.2 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/13/18
12/13
12:17
12/13/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/13/18
12/13
12:16
12/13/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$21.09

-1.23 (-5.51%)

12:15
12/13/18
12/13
12:15
12/13/18
12:15
Options
Stitch Fix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

, GS

Goldman Sachs

$176.57

-0.18 (-0.10%)

12:14
12/13/18
12/13
12:14
12/13/18
12:14
Hot Stocks
SoftBank Vision Fund leads $400M funding round in bio startup Zymergen »

Molecular manufacturing…

SFTBF

SoftBank

$0.00

(0.00%)

GS

Goldman Sachs

$176.57

-0.18 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BID

Sotheby's

$37.04

-0.06 (-0.16%)

12:12
12/13/18
12/13
12:12
12/13/18
12:12
Hot Stocks
Sotheby's Asia 2018 aggregate auction sales $985M, 'leads' Asia for last 3 years »

"2018 has been the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COHR

Coherent

$115.83

-1.93 (-1.64%)

12:10
12/13/18
12/13
12:10
12/13/18
12:10
Conference/Events
Coherent management to meet with Northcoast »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

XPO

XPO Logistics

$51.10

-9.15 (-15.19%)

, ECHO

Echo Global

$21.35

-0.41 (-1.88%)

12:05
12/13/18
12/13
12:05
12/13/18
12:05
Recommendations
XPO Logistics, Echo Global analyst commentary  »

XPO short report concerns…

XPO

XPO Logistics

$51.10

-9.15 (-15.19%)

ECHO

Echo Global

$21.35

-0.41 (-1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRX

Catalyst Pharmaceuticals

$2.40

0.01 (0.42%)

12:05
12/13/18
12/13
12:05
12/13/18
12:05
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst pricing for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SGAMY

Sega Sammy Holdings

$0.00

(0.00%)

, AMZN

Amazon.com

$1,659.51

-3.89 (-0.23%)

12:04
12/13/18
12/13
12:04
12/13/18
12:04
Periodicals
Sega rolls out classic Genesis games on Amazon Fire TV, Verge reports »

Sega (SGAMY) is bringing…

SGAMY

Sega Sammy Holdings

$0.00

(0.00%)

AMZN

Amazon.com

$1,659.51

-3.89 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

MSI

Motorola Solutions

$129.01

-0.64 (-0.49%)

12:03
12/13/18
12/13
12:03
12/13/18
12:03
Conference/Events
Motorola Solutions management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

GDI

Gardner Denver

$21.65

-0.2 (-0.92%)

12:01
12/13/18
12/13
12:01
12/13/18
12:01
Hot Stocks
Gardner Denver acquires MP Pumps for $58M in cash »

Gardner Denver Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NL

NL Industries

$3.92

(0.00%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
NL Industries falls -9.5% »

NL Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.34

-7.91 (-13.13%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
XPO Logistics falls -13.1% »

XPO Logistics is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$14.17

-5.99 (-29.71%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
Tailored Brands falls -29.6% »

Tailored Brands is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPDF

PPDAI Group

$4.96

0.5 (11.21%)

12:00
12/13/18
12/13
12:00
12/13/18
12:00
Hot Stocks
PPDAI Group rises 11.2% »

PPDAI Group is up 11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.